Rhinitis

PreHistin significantly reduces allergy symptoms in 714-patient phase III clinical trial

Published in Drug Week, November 25th, 2005

Cobalis Corp. (CLSC) announced the final statistical analyses on allergy patient symptom scores collected during the first of two required U.S. Food & Drug Administration (FDA)-approved phase III clinical trials for the company's antiallergy medication, PreHistin.

The study was the largest of its kind, according to Lyndon Mansfield, MD, Cobalis' senior medical advisor, and successfully concludes one of the most important milestones towards gaining FDA approval to market PreHistin in the U.S. as an over the counter (OTC) medication for preseasonal treatment of allergy symptoms.

The study demonstrated strong clinical and statistical significance that...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-11-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry